Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: A phase II study

Supportive Care in Cancer

Volumn 13, Issue 6, 2005, Pages 375-380

  Mandala M ^a   Cremonesi, M ^a   Rocca, A ^b   Cazzaniga, M ^a   Ferretti, G ^c   Di Cosimo, S ^c   Ghilardi, M ^a   Cabiddu, M ^a   Barni, S ^a  

^a TREVIGLIO HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Emesis; Midazolam

Indexed keywords

CISPLATIN; DEXAMETHASONE; GRANISETRON; METOCLOPRAMIDE; MIDAZOLAM;

ADULT; AGED; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LUNG CANCER; MALE; NAUSEA; NONPARAMETRIC TEST; PHASE 2 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; SCORING SYSTEM; SELF EVALUATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UROGENITAL TRACT CANCER; VISUAL ANALOG SCALE; VOMITING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; FEMALE; GRANISETRON; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; MIDDLE AGED; NAUSEA; NEOPLASMS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VOMITING;

EID: 21544479731     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0741-z     Document Type: Article

References (14)

1. Roila F (2003) MASCC Antiemetic Subcommittee. Multinational Association of Supportive Cancer Care (MASCC). Support Care Cancer 11:260-261
2. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208
3. Cooper S, Georgiou V (1992) The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses. Eur J Cancer 28A [Suppl 1]:S36-S38
4. Hesketh P (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191-196
5. Licitra L, Spinazze S, Roila F (2002) Antiemetic therapy. Crit Rev Oncol Hematol 43:93-101
6. Laszlo J, Clark RA, Hanson DC, Tyson L, Crumpler L, Gralla R (1985) Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects. J Clin Oncol 3:864-869
7. Kris MG, Gralla RJ, Clark RA, Tyson LB, Fiore JJ, Kelsen DP, Groshen S (1985) Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 69:1257-1262
8. Di Florio T (1992) The use of midazolam for persistent postoperative nausea and vomiting. Anaesth Intensive Care 20:383-386
9. Watts JC, Brierly A (2001) Midazolam for management of postoperative nausea. Anaesthesia 56:1129
10. Phillis JW, Bender AS, Wu PH (1980) Benzodiazepines inhibit adenosine up-take into rat brain synaptosomes. Brain Res 195:494-498
11. Racke K, Schwore H, Kilbinger H (1995) The pharmacology of 5-HT release from enterochromaffin cells. In: Reynolds WM, Andrews PRL, Davis CJ (eds) Serotonin and the scientific basis of antiemetic therapy. Oxford Clinical Communications, Oxford, pp 84-89
12. Potanovich LM, Pisters KM, Kris MG, Tyson LB, Clark RA, Baltzer L, Gralla RJ (1991) Midazolam in patients receiving anticancer chemotherapy and antiemetics. J Pain Symptom Manage 8:519-524
13. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
14. Aapro MS (2002) How do we manage patients with refractory or breakthrough emesis? Support Care Cancer 10:160-109